Ginkgo Bioworks Holdings, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Cell Engineering revenue (1) | $29,380 | $75,089 | $106,744 | $139,183 |
| Biosecurity revenue | 9,457 | 13,957 | 30,015 | 44,013 |
| Total revenue | 38,837 | 89,046 | 136,759 | 183,196 |
| Costs and operating expenses: | ||||
| Cost of Biosecurity revenue | 8,177 | 9,987 | 25,576 | 30,996 |
| Cost of other revenue | 4,625 | 2,016 | 14,095 | 3,930 |
| Research and development | 69,353 | 77,006 | 193,646 | 347,684 |
| General and administrative | 44,954 | 52,292 | 137,276 | 188,864 |
| Goodwill impairment | — | — | — | 47,858 |
| Restructuring charges | 1,745 | 2,949 | 10,692 | 20,015 |
| Total operating expenses | 128,854 | 144,250 | 381,285 | 639,347 |
| Loss from operations | (90,017) | (55,204) | (244,526) | (456,151) |
| Other income (expense): | ||||
| Interest income, net | 5,742 | 9,251 | 17,906 | 31,275 |
| Gain (loss) on investments | 3,684 | (6,912) | (238) | (16,282) |
| Loss on deconsolidation of subsidiary | — | (7,013) | — | (7,013) |
| Change in fair value of warrant liabilities | — | 1,528 | — | 5,701 |
| Other income (expense), net | (163) | 1,572 | (5,348) | 2,821 |
| Total other income (expense) | 9,263 | (1,574) | 12,320 | 16,502 |
| Loss before income taxes | (80,754) | (56,778) | (232,206) | (439,649) |
| Income tax (benefit) expense | 1 | (375) | (194) | (154) |
| Net loss | $(80,755) | $(56,403) | $(232,012) | $(439,495) |
| Net loss per share: | ||||
| Basic | $(1.45) | $(1.08) | $(4.22) | $(8.58) |
| Diluted | $(1.45) | $(1.08) | $(4.22) | $(8.58) |
| Weighted average common shares outstanding: | ||||
| Basic | 55,633,718 | 52,240,559 | 54,916,539 | 51,244,332 |
| Diluted | 55,633,718 | 52,246,129 | 54,916,539 | 51,249,902 |
| Comprehensive loss: | ||||
| Net loss | $(80,755) | $(56,403) | $(232,012) | $(439,495) |
| Other comprehensive (loss) income: | ||||
| Foreign currency translation adjustment | 27 | 494 | 3,462 | (2,713) |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | — | 1,492 | — | 1,492 |
| Unrealized gains (loss) on available-for-sale securities | 316 | — | 340 | — |
| Total other comprehensive (loss) income | 343 | 1,986 | 3,802 | (1,221) |
| Comprehensive loss | $(80,412) | $(54,417) | $(228,210) | $(440,716) |
(1)Includes related party revenue ofzero and $46,659 for the three months ended September 30, 2025 and 2024, respectively, and $8,518 and $51,990 for the nine months ended September 30, 2025 and 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.